Halozyme Receives Issuance Of New European Patent For ENHANZE Drug Delivery Platform; Will Be Validated In 37 European Countries And Expires On March 6, 2029
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been granted a new European patent for its ENHANZE drug delivery platform, which will be validated in 37 European countries and expires on March 6, 2029. A conference call is scheduled for June 6, 2024.
June 05, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics has been granted a new European patent for its ENHANZE drug delivery platform, which will be validated in 37 European countries and expires on March 6, 2029. This strengthens Halozyme's intellectual property portfolio and could enhance its market position in Europe.
The issuance of a new European patent for Halozyme's ENHANZE platform strengthens the company's intellectual property portfolio and could enhance its market position in Europe. This is likely to be viewed positively by investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100